Navigation Links
Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories

VIENNA, April 7 /PRNewswire/ -- Vela Laboratories announced today that it has received the GMP certificate for its analytical and quality control laboratories. "Good Manufacturing Practice" is a body of internationally accepted regulations set forth by EU and US drug agencies. GMP compliance ensures that pharmaceuticals , active ingredients and medical devices are pro­duced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life science industry. It is a major achievement for Vela Labs to have reached the GMP certification just 18 months since its formation," said Dr. Markus Fido, founder and CEO of Vela Laboratories. "Now that Vela Laboratories is GMP certified, its analytical services fully qualify to support clinical studies as well as regulatory submissions."

"GMP certification is an important milestone for our analytical services business. Now we will start to consistently expand our analytical methods portfolio that we are offering to the pharmaceutical and biotech industry," said Dr. Andreas Nechansky, founder of Vela Labo­ratories and Chief Operating Officer.

"Having achieved GMP compliance enables Vela to develop its therapeutic anti-cancer anti­bodies in the shortest time possible and with the highest quality," said Dr. Ralf Kircheis, founder of Vela Laboratories and Chief Scientific Officer.

About Vela Laboratories

Vela Laboratories (Vela pharmazeutische Entwicklung und Laboranalytik GmbH) provides a broad portfolio of analytical methods for the preclinical and clinical development including studies in support of regulatory submissions and product release for biopharmaceuticals.

Additionally, Vela Laboratories develops innovative immunotherapeutics for the treatment of cancer, including therapeutic antibodies and multi-epitope vaccines. Vela Laboratories' lead product, a humanized monoclonal antibody against a common tumor antigen, is in clinical development. In addition, Vela Laboratories also has development programs underway that aim at improving the efficacy and tolerability of therapeutic antibodies through targeted changes to the sugar structure of the antibody molecules.

The Company, headquartered in Vienna, Austria, was founded in November 2006. Vela Laboratories is funded by private investors, by grants from Austrian government agencies (AWS and ZIT/LISA) and through revenues generated by its analytical services business.


Jakob Koschutnig

Head Marketing & Sales

Vela Laboratories

Brunner Str. 69 / 3

1230 Vienna, Austria

Mobile: +43(0)699-1314-3-123

Fax: +43(0)1-890-597-9-10



SOURCE Vela Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. Stonegate Report About Unigene Laboratories Inc.
3. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
4. White Paper Details Environmental Health & Safety Compliance Strategies for Laboratories
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
7. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group announced that its scientific ... for isolating adipose-derived stem cells. The announcement starts a new phase toward launching the ... a component of the lipoaspirate obtained from liposuction of excess adipose tissue. , ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care hub ... northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. , ... cell medicine to patients from around the world. , The clinics will be headed by ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, ... assistant chemistry professor Jan Halámek, is taking crime ...   --> ...   --> --> ... UAlbany have discovered a straightforward concept for identifying ...
Breaking Biology Technology:
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):